Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit

Basit Öğe Kaydı
dc.authoridArı, Hatice Feray/0000-0002-2208-2524
dc.contributor.authorErsayoglu, Irem
dc.contributor.authorOzkaya, Pinar Yazici
dc.contributor.authorOzenen, Gizem Guner
dc.contributor.authorCebeci, Kubra
dc.contributor.authorAri, Hatice Feray
dc.contributor.authorBal, Zumru Sahbudak
dc.contributor.authorAydemir, Sabire Sohret
dc.date.accessioned2024-08-31T07:50:33Z
dc.date.available2024-08-31T07:50:33Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective To evaluate the effectiveness and safety of using tigecycline as a salvage therapy in critically ill children who did not respond to other antibiotics. Methods We conducted a retrospective cohort analysis that included children who received tigecycline for at least 48 hours and four doses during their pediatric intensive care unit admission. Demographic and clinical features of the subjects were evaluated through a comprehensive review of medical records. The effectiveness of tigecycline was assessed by thoroughly evaluating clinical and microbiological outcomes. Results During the study period, 72 pediatric patients with 88 episodes of infection received tigecycline according to antimicrobial susceptibility in 62.5% of cases and empirically in 37.5%. The median duration of tigecycline therapy was 10 days (range, 2-33 days). Klebsiella pneumoniae ( n = 17, 30.9%) was the most frequently isolated pathogen, followed by Acinetobacter baumannii ( n = 10, 18.1%). Ventilator-associated pneumonia was the most common infection ( n = 29). Of the 55 isolated pathogens, 43 were multidrug-resistant (MDR), and 2 were extensively drug-resistant (XDR) gram-negative bacteria. Clinical response and microbiological clearance were achieved in 42 and 50.9% of episodes, respectively. The overall mortality was 40.9%, with an attributable mortality rate of 29.5%. Conclusion Tigecycline could be used as a salvage therapy for critically ill pediatric patients infected with MDR or XDR pathogens in the lack of alternative treatment options.en_US
dc.identifier.doi10.1055/s-0044-1788342
dc.identifier.issn1305-7707
dc.identifier.issn1305-7693
dc.identifier.urihttps://doi.org/10.1055/s-0044-1788342
dc.identifier.urihttps://hdl.handle.net/11454/105281
dc.identifier.wosWOS:001283136000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofJournal of Pediatric Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectTigecyclineen_US
dc.subjectPediatric Intensive Care Uniten_US
dc.subjectMultidrug-Resistanten_US
dc.subjectExtensively Drug-Resistanten_US
dc.titleTigecycline Usage for Severe Infections in the Pediatric Intensive Care Uniten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu